ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) dampen the immune response thorough inhibition of T cell activation and proliferation and often are expanded in pathological conditions. Here, we studied the fate of MDSCs in cancer. Unexpectedly, MDSCs had lower viability and a shorter half-life in tumor-bearing mice compared with neutrophils and monocytes. The reduction of MDSC viability was due to increased apoptosis, which was mediated by increased expression of TNF-related apoptosis-induced ligand receptors (TRAIL-Rs) in these cells. Targeting TRAIL-Rs in naive mice did not affect myeloid cell populations, but it dramatically reduced the presence of MDSCs and improved immune responses in tumor-bearing mice. Treatment of myeloid cells with proinflammatory cytokines did not affect TRAIL-R expression; however, induction of ER stress in myeloid cells recapitulated changes in TRAIL-R expression observed in tumor-bearing hosts. The ER stress response was detected in MDSCs isolated from cancer patients and tumor-bearing mice, but not in control neutrophils or monocytes, and blockade of ER stress abrogated tumor-associated changes in TRAIL-Rs. Together, these data indicate that MDSC pathophysiology is linked to ER stress, which shortens the lifespan of these cells in the periphery and promotes expansion in BM. Furthermore, TRAIL-Rs can be considered as potential targets for selectively inhibiting MDSCs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, preclinical studies have demonstrated that TRAIL-R2 agonist antibodies can selectively target MDSC [321].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [321]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“CTLA4 antibody has been used to enhance the generation of tumor-reactive CD8 + T cells (23).”
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Walter, P., & Ron, D. (2011) · Science · doi:10.1126/science.1209038 · Cited by 5,924 · cited 1×
“The ER stress response pathway is a complex network responsible for maintaining ER homeostasis and is initiated by 3 protein sensors, PERK, IRE1 and ATF6, each of which activates a branch of the ER stress response (47).”
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
The unfolded protein response: controlling cell fate decisions under ER stress and beyond
Hetz, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3270 · Cited by 4,093 · cited 2×
“One of the hallmarks of ER stress is enlargement of the ER (30).”
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 4×
“These mechanisms include TNFR2 signaling, which supports MDSC survival through upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhibition of caspase-8 activity (8), signaling mediated via IL-4 α receptor (9), and decreased cell surface expression of FAS receptor, leading to diminished expression of IRF8…”
InfluentialSelf-citationTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 1×
“Myeloid cells, although expressing TRAIL, have low TRAIL-R expression and thus are resistant to killing by recombinant TRAIL (40).”
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Identification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221 · cited 1×
“However, the fact that spleen is a major source of extramedullar myelo-poiesis in TB mice and the data on high monocyte turnover in spleens (37, 38) may suggest that MDSCs rapidly leave spleen and are being replaced with newly produced cells.”
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 1×
“TB mice had a dramatic increase of MDSCs in spleens and peripheral blood (PB), where PMN-MDSCs represented more than 90% of all MDSCs (2, 13).”
BackgroundSelf-citationMovahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184 · cited 1×
“To determine whether TRAIL-Rs play a role in MDSC survival, we inhibited TRAIL signaling with OPG, a soluble decoy receptor for RANKL and TRAIL (18).”
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“KPC mice were described previously (52).”
Self-citationKo, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862 · cited 2×
“PMNs, with the same phenotype, were purified from PB of the same patients and from healthy donors using the standard neutrophil isolation protocol (33).”
MethodMolecular mechanisms regulating myeloid-derived suppressor cell differentiation and function
Condamine, T., & Gabrilovich, D. I. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.10.002 · Cited by 845 · cited 2×
“Expansion of MDSCs in cancer is controlled by several growth factors and cytokines, with GM-CSF being the most prominent (6, 7).”
Self-citationThe TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2465 · Cited by 834 · cited 6×
“To determine whether TRAIL-Rs play a role in MDSC survival, we inhibited TRAIL signaling with OPG, a soluble decoy receptor for RANKL and TRAIL (18).”
InfluentialLipid accumulation and dendritic cell dysfunction in cancer
Herber, D. L., Cao, W., Nefedova, Y., Novitskiy, S. V., Nagaraj, S., Tyurin, V. A., Corzo, A., Cho, H.-I., Celis, E., Lennox, B., et al. (2010) · Nature Medicine · doi:10.1038/nm.2172 · Cited by 735
Self-citationOrigins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689 · cited 1×
“However, the fact that spleen is a major source of extramedullar myelo-poiesis in TB mice and the data on high monocyte turnover in spleens (37, 38) may suggest that MDSCs rapidly leave spleen and are being replaced with newly produced cells.”
Myeloid-derived suppressor cell heterogeneity and subset definition
Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., & Bronte, V. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.01.021 · Cited by 630 · cited 1×
“MDSCs have a distinct gene expression profile and a number of biochemical and functional differences from normal monocytes and PMNs (4, 5).”
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death
Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S., Green, D. R., & Schoenberger, S. P. (2005) · Nature · doi:10.1038/nature03337 · Cited by 619
Santos, C. X. C., Tanaka, L. Y., Wosniak, J., & Laurindo, F. R. M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2625 · Cited by 572 · cited 1×
“Several factors could induce ER stress in MDSCs. MDSCs are known to have high level of ROS, one of the major inducers of the ER stress response (49).”
The Role of Endoplasmic Reticulum in Hepatic Lipid Homeostasis and Stress Signaling
Fu, S., Watkins, S. M., & Hotamisligil, G. S. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.007 · Cited by 545 · cited 1×
“Lipids represent another potent ER stress inducer (50), and lipid accumulation was shown to be associated with DCs (51) and other myeloid cells (data not shown).”
Youn, J.-I., Collazo, M., Shalova, I. N., Biswas, S. K., & Gabrilovich, D. I. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0311177 · Cited by 510 · cited 1×
“MDSCs have a distinct gene expression profile and a number of biochemical and functional differences from normal monocytes and PMNs (4, 5).”
Self-citationTRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458 · cited 1×
“DR5 expression in tumor cells can be induced by NF-κ B, which is regulated by proinflammatory cytokines (25).”
Myeloid derived suppressor cells in human diseases
Greten, T. F., Manns, M. P., & Korangy, F. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.01.003 · Cited by 398 · cited 1×
“These cells represent the most abundant group of MDSCs in patients with many types of cancer (31, 32).”
TNF signaling drives myeloid-derived suppressor cell accumulation
Zhao, X., Rong, L., Zhao, X., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64115 · Cited by 378 · cited 1×
“These mechanisms include TNFR2 signaling, which supports MDSC survival through upregulation of cellular FLICE-inhibitory protein (c-FLIP) and inhibition of caspase-8 activity (8), signaling mediated via IL-4α receptor (9), and decreased cell surface expression of FAS receptor, leading to diminished expression of IRF8…”
BackgroundYoun, J.-I., Kumar, V., Collazo, M., Nefedova, Y., Condamine, T., Cheng, P., Villagra, A., Antonia, S., McCaffrey, J. C., Fishman, M., et al. (2013) · Nature Immunology · doi:10.1038/ni.2526 · Cited by 350
Self-citationDifferential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., & Chan, F. K.-M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507329102 · Cited by 232 · cited 1×
“However, DCR2 may provide antiapoptotic signals neutralizing TRAIL-R signaling, whereas DCR1 inhibits TRAIL-induced apoptosis by competing for TRAIL binding (43, 44).”
BackgroundInduction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
Takeda, K., Yamaguchi, N., Akiba, H., Kojima, Y., Hayakawa, Y., Tanner, J. E., Sayers, T. J., Seki, N., Okumura, K., Yagita, H., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031457 · Cited by 206 · cited 1×
“In previous studies, treatment of mice bearing DR5-expressing tumors with agonistic MD5-1 mAb resulted in antitumor effects (41, 42).”
Self-citationMyeloid-derived Suppressor Cells in Cancer Patients: A Clinical Perspective
Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V., & Mandruzzato, S. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318242169f · Cited by 202 · cited 1×
“These cells represent the most abundant group of MDSCs in patients with many types of cancer (31, 32).”
Ilkovitch, D., & Lopez, D. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4625 · Cited by 188
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
Finnberg, N., Klein-Szanto, A. J. P., & El-Deiry, W. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci29900 · Cited by 180 · cited 1×
“To study the implication of TRAIL signaling on MDSC survival, we used myeloid cells from Dr5 KO mice (19, 20).”
Self-citationAptamer-Mediated Blockade of IL4Rα Triggers Apoptosis of MDSCs and Limits Tumor Progression
Roth, F., De La Fuente, A. C., Vella, J. L., Zoso, A., Inverardi, L., & Serafini, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2772 · Cited by 173 · cited 2×
“Agonistic DR5 antibodies and recombinant TRAIL have been previously used to target tumor cells in several clinical trials with modest results (9, 16, 17), partially attributed to the variability of TRAILR expression in tumor cells.”
BackgroundTRAIL receptor signaling and therapeutics
Abdulghani, J., & El‐Deiry, W. S. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.519701 · Cited by 171 · cited 2×
“Agonistic DR5 antibodies and recombinant TRAIL have been previously used to target tumor cells in several clinical trials with modest results (9, 16, 17), partially attributed to the variability of TRAIL-R expression in tumor cells.”
Self-citationSinha, P., Chornoguz, O., Clements, V. K., Artemenko, K. A., Zubarev, R. A., & Ostrand‐Rosenberg, S. (2011) · Blood · doi:10.1182/blood-2010-11-321752 · Cited by 165 · cited 3×
“demonstrated the possibility of CTLs killing MDSCs via FAS-FASL–mediated apoptosis (12).”
BackgroundResultShiraishi, T., Yoshida, T., Nakata, S., Horinaka, M., Wakada, M., Mizutani, Y., Miki, T., & Sakai, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0312 · Cited by 158 · cited 11×
“To determine whether TRAIL-Rs play a role in MDSC survival, we inhibited TRAIL signaling with OPG, a soluble decoy receptor for RANKL and TRAIL (18).”
InfluentialShetty, S., Graham, B. A., Brown, J. G., Hu, X., Vegh-Yarema, N., Harding, G. A., Paul, J. T., & Gibson, S. B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5404-5416.2005 · Cited by 150 · cited 1×
“Coincidently, NF-κB triggered by many proinflammatory factors regulates TRAIL-R expression (45).”
BackgroundDeath Receptor 5 Signaling Promotes Hepatocyte Lipoapoptosis
Cazanave, S. C., Mott, J. L., Bronk, S. F., Werneburg, N. W., Fingas, C. D., Meng, X. W., Finnberg, N. K., El‐Deiry, W. S., Kaufmann, S. H., & Gores, G. J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.280420 · Cited by 144 · cited 2×
“Since it is known that lymphodepletion can induce homeostatic proliferation of lymphocytes (24), we hypothesized that the reduced survival of MDSCs in the periphery could contribute to increased production of these cells in the BM.”
Self-citationDR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis
Finnberg, N., Gruber, J. J., Fei, P., Rudolph, D., Bric, A., Kim, S.-H., Burns, T. F., Ajuha, H., Page, R., Wu, G. S., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.2000-2013.2005 · Cited by 116 · cited 2×
“To study the implication of TRAIL signaling on MDSC survival, we used myeloid cells from Dr5 KO mice (19, 20).”
Self-citationNagaraj, S., Nelson, A., Youn, J., Cheng, P., Quiceno, D. G., & Gabrilovich, D. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2863 · Cited by 108
Self-citationCaspase inhibitors in prevention of apoptosis
Rudel, T. (1999) · Herz · doi:10.1007/bf03044967 · Cited by 105 · cited 1×
“Inhibition of caspase-8 with the specific inhibitor Z-IETD-FMK (14) substantially reduced apoptosis of MDSCs (Figure 2D), which suggests that this process was mediated by caspase-8 and most likely involved the extrinsic death receptor pathway (15).”
Chen, S., Akbar, S. M. F., Abe, M., Hiasa, Y., & Onji, M. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04445.x · Cited by 105 · cited 1×
“These data are consistent with several observations demonstrating that the liver is a site of large MDSC accumulation in TB mice and chronic infections (35, 36).”
ResultRibechini, E., Leenen, P. J. M., & Lutz, M. B. (2009) · European Journal of Immunology · doi:10.1002/eji.200939530 · Cited by 92 · cited 1×
“We modeled this situation in tumor-free mice by using Gr1 mAb in vivo, which depletes Gr1 + PMNs and monocytes in spleen and PB, but not in BM (39).”
Liu, G., Su, L., Hao, X., Zhong, N., Zhong, D., Singhal, S., & Liu, X. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01401.x · Cited by 87 · cited 1×
“DR5 expression in tumor cells can also be induced by ER stress via spliced XBP1, a major mediator of the IRE1 pathway, and C/EBP homologous protein (CHOP), a downstream molecule of the PERK pathway (24, 26–29).”
Martín‐Pérez, R., Niwa, M., & López‐Rivas, A. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0673-2 · Cited by 73
The Role of Activation-Induced Cell Death in the Differentiation of T-Helper-Cell Subsets
Roberts, A. I., Devadas, S., Zhang, X., Zhang, L., Keegan, A. D., Greeneltch, K. M., Solomon, J., Wei, L., Das, J., Shi, Y., et al. (2003) · Immunologic Research · doi:10.1385/ir:28:3:285 · Cited by 71 · cited 1×
“Since activated T cells express DR5 (21, 22), we tested the possibility that triggering of the receptor could result in activation of T cells.”
Chornoguz, O., Grmai, L., Sinha, P., Artemenko, K. A., Zubarev, R. A., & Ostrand-Rosenberg, S. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.002980 · Cited by 69 · cited 1×
“MDSCs induced in highly inflammatory settings had increased resistance to FAS-mediated apoptosis (11).”
Hu, X., Bardhan, K., Paschall, A. V., Yang, D., Waller, J. L., Park, M. A., Nayak-Kapoor, A., Samuel, T. A., Abrams, S. I., & Liu, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.434530 · Cited by 67 · cited 7×
“Hu and colleagues measured apoptosis of MDSCs after 24 hours culture and showed that it was slightly lower that in control cells (10).”
InfluentialTian, X., Ye, J., Alonso‐Basanta, M., Hahn, S. M., Koumenis, C., & Dorsey, J. F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.197665 · Cited by 64
Haynes, N. M., Hawkins, E. D., Li, M., McLaughlin, N. M., Hämmerling, G. J., Schwendener, R. A., Winoto, A., Wensky, A. K., Yagita∥, H., Takeda, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903624 · Cited by 61 · cited 1×
“In previous studies, treatment of mice bearing DR5-expressing tumors with agonistic MD5-1 mAb resulted in antitumor effects (41, 42).”
Self-citationTranscription factors in myeloid-derived suppressor cell recruitment and function
Sonda, N., Chioda, M., Zilio, S., Simonato, F., & Bronte, V. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.006 · Cited by 61
Role of Endoplasmic Reticulum Stress in α-TEA Mediated TRAIL/DR5 Death Receptor Dependent Apoptosis
Tiwary, R., Yu, W., Li, J., Park, S.-K., Sanders, B. G., & Kline, K. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011865 · Cited by 59
Thapsigargin potentiates TRAIL-induced apoptosis in giant cell tumor of bone
Huang, L., Xu, J., Li, K., Zheng, M., & Kumta, S. M. (2004) · Bone · doi:10.1016/j.bone.2004.02.005 · Cited by 16 · cited 1×
“These data are consistent with a previous report showing that thapsigargin could decrease TRAIL decoy receptor expression in giant cell tumor of bone (48).”
陳, 式. (2013) · Medical Entomology and Zoology · Cited by 12
Research works printed but not linked: 1
- Johnstone, 2008, Cancer., 8, 782
Cited by
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
“Targeting the TRAIL receptor can be a potent and selective method of MDSC depletion (30).”
BackgroundMethodSelf-citationMyeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Self-citationMyeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Self-citationEndoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
Metadata
- Authors
- Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., Knight, S. C., Yagita, H., McCaffrey, J. C., Antonia, S., Hockstein, N., Witt, R., Masters, G., Bauer, T., & Gabrilovich, D. I.
- Affiliations
- The Wistar Institute (US)
- Moffitt Cancer Center (US)
- Penn State Cancer Institute (US)
- Abramson Cancer Center (US)
- Imperial College London (GB)
- Christiana Care Health System (US)
- Corresponding author
- Gabrilovich, Dmitry I.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-05-01
- Volume
- 124
- Issue
- 6
- Pages
- 2626-2639
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4038578
- OpenAlex
- W2153232526
- Cited by
- 365
- References
- 54
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 46 · 2023: 34 · 2022: 40 · 2021: 40 · 2020: 40 · 2019: 29 · 2018: 24 · 2017: 29 · 2016: 21 · 2015: 15 · 2014: 7
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Moffitt Cancer Center
- National Institutes of Health
- Biotechnology and Biological Sciences Research Council (BBS/E/F/00044446)
- Japan Society for the Promotion of Science (26290059)
- National Cancer Institute (R01CA084488, CA084488, P50CA119997, P30CA076292, P30CA010815)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- myeloid-derived suppressor cells, endoplasmic reticulum stress, TRAIL receptors, apoptosis, tumor immunosuppression, bone marrow expansion, inflammatory cytokines
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Biological, Apoptosis, Myeloid Cells, Cell Line, Tumor, Mice, Receptors, TNF-Related Apoptosis-Inducing Ligand, Endoplasmic Reticulum Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.